Addex Therapeutics (ADXN) officer discloses multiple stock-option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Addex Therapeutics Ltd. principal accounting officer Lenaic Nathanael Teyssedou filed an initial ownership report showing multiple stock-option awards over Addex common shares. These options are rights to buy shares at fixed prices and represent existing compensation grants, not new share purchases or sales.
The filing lists several option grants with exercise prices of $0.1660, $0.0550, and $0.0640 per share, expiring between 2027 and 2034. According to the footnotes, each option gives the right to buy one ADXN share, vesting in equal monthly installments over four years, and the exercise prices are reported in U.S. dollars using a $1.2769 per CHF $1.00 exchange rate as of March 12, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Teyssedou Lenaic Nathanael
Role
PRINCIPAL ACCOUNTING OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock-option (Right to Buy) | -- | -- | -- |
| holding | Stock-option (Right to Buy) | -- | -- | -- |
| holding | Stock-option (Right to Buy) | -- | -- | -- |
| holding | Stock-option (Right to Buy) | -- | -- | -- |
| holding | Stock-option (Right to Buy) | -- | -- | -- |
| holding | Stock-option (Right to Buy) | -- | -- | -- |
| holding | Stock-option (Right to Buy) | -- | -- | -- |
| holding | Stock-option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock-option (Right to Buy) — 37,770 shares (Direct)
Footnotes (1)
- The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.
